Multi-omics reveals regulatory networks and critical early-warning factors for severe disease progression in diabetic patients infected with SARS-CoV-2.
Diabetic patients face elevated risks of severe COVID-19, yet the molecular underpinnings of disease progression, particularly for Omicron subvariants, which have predominated since late 2021, remain poorly defined. This observational study leverages a cohort recruited during China's Omicron peak (December 2022-February 2023) to delineate multi-omic signatures underlying severe diabetic COVID-19.
We enrolled 55 patients across five clinical strata: non-diabetic mild/severe, diabetic mild/severe/fatal. Integrated 4D-DIA proteomics and LC/GC-MS metabolomics were applied, adjusting for confounders while retaining secondary infections as integral disease features.
Diabetic patients exhibited immune exhaustion with elevated IL-6/IL-10, blunted antiviral responses, and high secondary infection rates. We identified 62 diabetes-unique molecules associated with coordinated dysregulation across six pathways: oxidative stress, ferroptosis, glycolytic dysfunction, lipid remodeling, insulin signaling, and endothelial injury. A graded molecular signature tracked clinical deterioration: progressive depletion of GP1BB and PRG3, coupled with stepwise elevation of MMP-3/LOXL1 and Dl-Xylose. Fatal cases further revealed a metabolic substrate misalignment, glycolytic flux adduct accumulation paradoxically coexisting with glucose, lactate, ornithine depletion, suggesting terminal fuel utilization failure. Stage-dependent shifts of stress mediators (e.g., GSK3B, ALDH9A1) distinguished severe from fatal outcomes, implying transition from compensatory adaptation to homeostatic exhaustion.
Severe diabetic COVID-19 is characterized by progressive immune-metabolic collapse. GP1BB, MMP-3, and Dl-Xylose warrant evaluation as early-warning biomarkers, while ornithine and PC(18:2) may track homeostatic reserve depletion in terminal disease. Together, these findings identify candidate biomarkers and pathway nodes that, with further validation, could contribute to risk-stratification and therapeutic strategies for diabetic patients with severe viral infections.
We enrolled 55 patients across five clinical strata: non-diabetic mild/severe, diabetic mild/severe/fatal. Integrated 4D-DIA proteomics and LC/GC-MS metabolomics were applied, adjusting for confounders while retaining secondary infections as integral disease features.
Diabetic patients exhibited immune exhaustion with elevated IL-6/IL-10, blunted antiviral responses, and high secondary infection rates. We identified 62 diabetes-unique molecules associated with coordinated dysregulation across six pathways: oxidative stress, ferroptosis, glycolytic dysfunction, lipid remodeling, insulin signaling, and endothelial injury. A graded molecular signature tracked clinical deterioration: progressive depletion of GP1BB and PRG3, coupled with stepwise elevation of MMP-3/LOXL1 and Dl-Xylose. Fatal cases further revealed a metabolic substrate misalignment, glycolytic flux adduct accumulation paradoxically coexisting with glucose, lactate, ornithine depletion, suggesting terminal fuel utilization failure. Stage-dependent shifts of stress mediators (e.g., GSK3B, ALDH9A1) distinguished severe from fatal outcomes, implying transition from compensatory adaptation to homeostatic exhaustion.
Severe diabetic COVID-19 is characterized by progressive immune-metabolic collapse. GP1BB, MMP-3, and Dl-Xylose warrant evaluation as early-warning biomarkers, while ornithine and PC(18:2) may track homeostatic reserve depletion in terminal disease. Together, these findings identify candidate biomarkers and pathway nodes that, with further validation, could contribute to risk-stratification and therapeutic strategies for diabetic patients with severe viral infections.
Authors
Dong Dong, Yu Yu, Xiao Xiao, Zhou Zhou, Tang Tang, Li Li, Qin Qin, Ma Ma, Li Li
View on Pubmed